Cargando…

Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes

BACKGROUND: Mechanistic insights of glucagon‐like peptide‐1 receptor agonists remain incompletely identified, despite the efficacy in heart failure observed in clinical trials. Here, we evaluated the effects of dulaglutide on heart complications and illuminated its underlying mechanism. METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Saiyang, Zhang, Min, Shi, Wenke, Xing, Yun, Huang, Yan, Fang, Wen‐xi, Liu, Shi‐qiang, Chen, Meng‐Ya, Zhang, Tong, Chen, Si, Zeng, Xiaofeng, Wang, Shasha, Deng, Wei, Tang, Qizhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673690/ https://www.ncbi.nlm.nih.gov/pubmed/36172969 http://dx.doi.org/10.1161/JAHA.122.026728

Ejemplares similares

Diminished arachidonate 5-lipoxygenase perturbs phase separation and transcriptional response of Runx2 to reverse pathological ventricular remodeling
por: Xie, Saiyang, et al.
Publicado: (2022)

Activation of Nrf2 by Lithospermic Acid Ameliorates Myocardial Ischemia and Reperfusion Injury by Promoting Phosphorylation of AMP-Activated Protein Kinase α (AMPKα)
por: Zhang, Min, et al.
Publicado: (2021)

Cardiac fibroblast heat shock protein 47 aggravates cardiac fibrosis post myocardial ischemia–reperfusion injury by encouraging ubiquitin specific peptidase 10 dependent Smad4 deubiquitination
por: Xie, Saiyang, et al.
Publicado: (2022)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study
por: Singh, Priyamvada, et al.
Publicado: (2020)

Activation of Toll‐like receptor 7 provides cardioprotection in septic cardiomyopathy‐induced systolic dysfunction
por: Saiyang, Xie, et al.
Publicado: (2021)

Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus
por: Du, Juan, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review
por: Zhang, Lin, et al.
Publicado: (2016)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson, Angela M, et al.
Publicado: (2016)

Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes
por: Su, Yu, et al.
Publicado: (2023)

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
por: Alatorre, Carlos, et al.
Publicado: (2017)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes
por: Alduraibi, Rabia Khalid, et al.
Publicado: (2023)

Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications
por: Xie, Saiyang, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
por: Bohne, Loryn J., et al.
Publicado: (2023)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes
por: Ruda, Alexandru Ioan, et al.
Publicado: (2023)

Andrographolide Protects Against Adverse Cardiac Remodeling After Myocardial Infarction through Enhancing Nrf2 Signaling Pathway
por: Xie, Saiyang, et al.
Publicado: (2020)

Effects of dulaglutide combined with insulin degludec on glucose fluctuations and appetite in type 2 diabetes
por: Huang, Jinxin, et al.
Publicado: (2023)

A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
por: An, In Bok, et al.
Publicado: (2020)

Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
por: Edwards, Krystal L, et al.
Publicado: (2015)

The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
por: Xie, Dandan, et al.
Publicado: (2022)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
por: Miyagawa, J., et al.
Publicado: (2015)

Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes
por: Kim, Pyung-Hwan, et al.
Publicado: (2012)

Glucagon−like Peptide−1 and−2 Levels in Children with Diabetic Ketoacidosis
por: Akıncı, Ayşehan, et al.
Publicado: (2009)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
por: Larsen, Matthias Ploug, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis
por: Chen, Han, et al.
Publicado: (2023)

Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta−analysis
por: Luan, Sisi, et al.
Publicado: (2022)

Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis
por: Xie, Fei-Fei, et al.
Publicado: (2022)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan
por: Kamin, Matiullah, et al.
Publicado: (2021)

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mj0cjvo00bh4fd1m5nufveccqv